EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics

J M Samuels iD, C R Williams iD, M B Patel, W H Self, L M Funk, C Roumie, M D Spann, C J Northup, F Ye, R Irlmeier, I Sohn, Y Zhu und 1 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von J M Samuels und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Bariatric Surgery, Gastric Bypass, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences/National Institutes of Health, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after Roux‐en‐Y gastric bypass (RYGB) in patients with persistent obesity (body mass index [BMI] ≥ 30 kg/m 2 ). Materials and Methods This randomized, open‐label proof‐of‐concept trial compares 24 weeks of TRZ with SOC versus SOC alone after RYGB. The primary outcome is total percent weight change from baseline to 24 weeks after trial initiation. Patients aged 25–65 with BMI ≥ 30 kg/m 2 enroled 12 months after RYGB are randomized 1:1 to 24 weeks of TRZ or SOC. Exclusion criteria include: type 1 diabetes, type 2 diabetes treatment other than metformin, conversion to RYGB from prior bariatric surgery, and GLP1RA use in the past 3 months.

Results

The study enroled 33 patients, with 5 withdrawals prior to completing a baseline visit, resulting in a final sample of 28 patients. The final cohort is 82% female, 75% white, median age 42.0 years, pre‐surgery BMI of 48.3 kg/m 2 , baseline BMI at randomization of 36.0 kg/m 2 and baseline weight of 95.6 kg.

Conclusions

GRABS is the first randomized trial to investigate GLP1RA effectiveness in patients with persistent obesity following RYGB, with the potential to inform synergistic adjuvant strategies to enhance surgical weight loss. Trial Registration ClinicalTrials.gov identifier: NCT06162715

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryGastric BypassGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesity, MorbidAdultAgedFemaleHumansMaleMiddle AgedBody Mass IndexObesityPostoperative CareProof of Concept StudyRandomized Controlled Trials as TopicTirzepatideTreatment OutcomeWeight LossClinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

GLP‐1 receptor agonistGRABS trialbariatric surgerymultimodal obesity treatmentobesity management medicationweight recurrence

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTirzepatide

Autor:innen und Institutionen

  • Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Vanderbilt Medical Student Research Training Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Surgery, William S. Middleton VA, Madison, Wisconsin, USA.
  • Department of Surgery, William S. Middleton Veterans Health Administration Hospital, Madison, Wisconsin, USA.

ORCID-Profile: J M Samuels, C R Williams

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences/National Institutes of Health
  • NIDDK NIH HHS
  • Vanderbilt Digestive Disease Research Center
  • Vanderbilt Diabetes and Research Training Center
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health
  • Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center

Zitieren

APA

Samuels, J. M., Williams, C. R., Patel, M. B., Self, W. H., Funk, L. M., Roumie, C., Spann, M. D., Northup, C. J., Ye, F., Irlmeier, R., Sohn, I., Zhu, Y., & Niswender, K. (2026). GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71320

Vancouver

Samuels JM, Williams CR, Patel MB, Self WH, Funk LM, Roumie C, et al. GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71320

BibTeX
@article{Samuels2026,
  author = {Samuels, J M and Williams, C R and Patel, M B and Self, W H and Funk, L M and Roumie, C and Spann, M D and Northup, C J and Ye, F and Irlmeier, R and Sohn, I and Zhu, Y and Niswender, K},
  title = {GLP ‐1 Receptor Agonists Post‐Bariatric Surgery ( GRABS ) Trial: Rationale, Design and Baseline Characteristics},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71320}
}
Kostenlos starten →